Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (337)	5/18/2005 9:46:44 AM
From: nigel bates	Read Replies (1) \| Respond to of 510

Ciphergen Announces Issuance of Patent for Multi-marker Diagnostics Using SELDI ProteinChip(R) Technology Wednesday May 18, 9:00 am ET Complements Existing Patents Covering Ciphergen's Pattern Track(TM) Biomarker Discovery to Assay Process FREMONT, Calif., May 18 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH - News) announced today that it has been granted U.S. Patent 6,844,165, directed to the detection of multiple diagnostic markers by SELDI-TOF-MS for the diagnosis of disease. Multi-marker assays using Ciphergen's patented SELDI ProteinChip® System are the basis for the clinical diagnostic tests that Ciphergen Diagnostics is currently developing for commercialization. Ciphergen has several issued United States patents that cover aspects of our integrated Pattern Track(TM) biomarker discovery, validation and assay process. These include U.S. patent 5,719,060, which covers the basic SELDI process; U.S. patents 6,225,047 and 6,579,719, which cover biomarker discovery through protein profile difference mapping using SELDI; U.S. patent 6,675,104, which covers pattern proteomics based discovery, validation and classification of biomarker combinations (multi-markers) using a multivariate pattern recognition algorithm; and this new patent (6,844,165), which covers multi-marker diagnostic assays performed on the SELDI platform. "We believe combinations of specific, identified protein biomarkers can provide greater predictive diagnostic value than a single biomarker," said William E. Rich, President and CEO of Ciphergen. "Ciphergen's family of ProteinChip technology patents form a powerful portfolio supporting our leadership position in biomarker proteomics, enabling Ciphergen to continue as the premier innovator in translating pattern-based biomarker discovery to multi-marker-based diagnostics through our Pattern Track(TM) process."...